What are the recommended diagnostic and treatment approaches for patients with Brugada syndrome?

Brugada Syndrome: Diagnostic and Treatment Approach

For symptomatic Brugada syndrome patients with spontaneous Type 1 ECG pattern and cardiac arrest, sustained ventricular arrhythmia, or syncope presumed due to arrhythmia, an ICD is the definitive treatment; asymptomatic patients with only inducible Type 1 pattern require observation alone. 1

Diagnostic Approach

ECG Pattern Recognition

• Spontaneous Type 1 Brugada pattern (coved ST-segment elevation >2mm in ≥1 right precordial leads V1-V3 followed by negative T-wave) establishes the diagnosis 2
• Sodium channel blocker challenge (ajmaline, flecainide, procainamide, or pilsicainide) can unmask Type 1 pattern when suspected but not spontaneously present 1
  • This is a Class IIa recommendation for patients with suspected Brugada syndrome lacking spontaneous Type 1 pattern 1
  • Ajmaline is most commonly used for provocation testing 3

Risk Stratification Considerations

• Electrophysiological study with programmed ventricular stimulation using single and double extrastimuli may be considered for further risk stratification in asymptomatic patients with spontaneous Type 1 pattern, though this carries only Class IIb recommendation 1
• Distinguishing arrhythmic syncope from benign neurally-mediated syncope is critical, as both are common in this population 4

Genetic Testing

• Genetic counseling and testing may be useful to facilitate cascade screening of relatives (Class IIb recommendation) 1

Treatment Algorithm by Clinical Presentation

High-Risk Symptomatic Patients

ICD implantation is mandatory for patients with: 1

• Spontaneous Type 1 pattern AND cardiac arrest
• Spontaneous Type 1 pattern AND sustained ventricular arrhythmia
• Spontaneous Type 1 pattern AND recent syncope presumed due to ventricular arrhythmia
• Expected meaningful survival >1 year required

Patients Declining or Ineligible for ICD

Quinidine or catheter ablation is recommended for spontaneous Type 1 pattern with symptomatic ventricular arrhythmia when ICD is not feasible 1

Recurrent ICD Shocks

Intensification with quinidine or catheter ablation is required for patients experiencing recurrent ICD shocks for polymorphic VT 1

• Catheter ablation shows 87.1% non-inducibility of ventricular arrhythmia post-procedure 3
• Substrate-based ablation strategy is used in 87% of cases, often with sodium channel blocker augmentation 3
• Over 28-month follow-up, 17.6% experience recurrence of ventricular arrhythmia after ablation 3

Asymptomatic Patients

Observation without therapy is the standard approach for: 1

• Asymptomatic patients with only inducible Type 1 pattern (Class I recommendation)
• Asymptomatic patients with spontaneous Type 1 pattern (though electrophysiology study may be considered for further stratification)

Critical Pitfalls to Avoid

• Do not treat asymptomatic patients with only drug-induced Type 1 pattern—observation is the guideline-recommended approach, as these patients have lower risk 1
• Avoid misclassifying benign syncope as arrhythmic—neurally-mediated syncope is very common in Brugada patients and does not warrant ICD 4
• Recognize that Type 2 pattern alone is insufficient for diagnosis—provocation testing is needed to confirm Type 1 pattern 5
• Exercise caution with local anesthetics—they block the same sodium channels that are dysfunctional in Brugada syndrome 6

Key Nuances in Management

The 2017 AHA/ACC/HRS guidelines provide clear Class I recommendations for high-risk symptomatic patients but leave significant gray zones for asymptomatic or intermediate-risk presentations 7. The challenge lies in distinguishing truly arrhythmic syncope from benign causes, as both are prevalent in this population 4. While catheter ablation is emerging as an effective strategy with high acute success rates, long-term recurrence remains a concern in approximately one-fifth of patients 3.